Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours

标题
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours
作者
关键词
-
出版物
EUROPEAN JOURNAL OF CANCER
Volume 50, Issue 17, Pages 2897-2904
出版商
Elsevier BV
发表日期
2014-09-25
DOI
10.1016/j.ejca.2014.07.017

向作者/读者发起求助以获取更多资源

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started